MedTrace Logo

Study of Histrelin Subdermal Implant in Patients With Prostate Cancer

NCT01394263 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2024-01-02

No results posted yet for this study

Summary

This trial was an open-label, multi-national, randomized, parallel treatment, active-control multicenter study in adult males with documented metastatic prostate cancer disease who were judged to be candidates for hormone therapy.

Conditions

Interventions

DRUG

Histrelin hydrogel implant

50 mg histrelin acetate in hyrogel implant

DRUG

Zoladex goserelin implant

goserelin implant injection.

Sponsors & Collaborators

  • Endo Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-05-31
Primary Completion
2001-12-31
Completion
2003-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01394263 on ClinicalTrials.gov